Pharmaceutical News

RSS

The Chinese acute coronary syndrome drug market to grow from $326M in 2010 to $448M in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the acute coronary syndrome (ACS) drug market in China will grow from $326 million in 2010 to $448 million in 2015.

21 Nov 2011

ChanRx to evaluate AFIB drug, vanoxerine with closed Series A funding

ChanRx is developing a superior drug for treatment of atrial fibrillation (AFIB), and has closed its Series A funding with investments from Sante Ventures and company founder, Dr. Arthur "Buzz" Brown. The company, a spin out of Cleveland-based ChanTest, will use the funding to further evaluate the safety and efficacy of its proprietary AFIB drug, vanoxerine.

21 Nov 2011

SAFC commences process validation activities for Oncolytics' REOLYSIN

Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.

21 Nov 2011

Australia's TGA grants market authorisation for Pierre Fabre Médicament's milnacipran to treat fibromyalgia

The Therapeutic Goods Administration (TGA), Australia's regulatory body for therapeutic products, granted Pierre Fabre Médicament's milnacipran market authorisation for the treatment of fibromyalgia.

21 Nov 2011

PLoS ONE publishes study on darinaparsin, a multivalent chemotherapeutic

ZIOPHARM Oncology, Inc. announced today the publication of a darinaparsin (Zinapar or ZIO-101) study in the PLoS ONE, an international, peer-reviewed, open-access, online publication of the Public Library of Science.

21 Nov 2011

Impax initiates patent challenge related to Fentora

Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed in the Orange Book in connection with Fentora® (fentanyl buccal tablets, 100 mcg, 200 mcg, 400 mcg, 600 mcg and 800 mcg).

21 Nov 2011

IGI develops and submits two more ANDAs to the FDA

IGI Laboratories, Inc., a New Jersey based formulation and manufacturing company, today announced that it has submitted two more abbreviated new drug applications (ANDAs) to the US FDA.

21 Nov 2011

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.

21 Nov 2011

Cambridge Theranostics' liquidators set deadline for offers

Cambridge Theranostics' liquidators have set a deadline of 9 December for offers for the company's business, which includes the intellectual property of its principal product, Ateronon.

21 Nov 2011

Mylan settles Vivelle-Dot patent litigation lawsuit with Novartis

Mylan Inc. today announced that it has settled a patent litigation lawsuit with Novartis Pharmaceuticals Corporation related to Vivelle-Dot® (Estradiol Transdermal System USP, Twice-Weekly, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day and 0.075 mg/day and 0.1 mg/day).

21 Nov 2011

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) on November 18, 2011 to remove the pre-treatment biodistribution evaluation requirement using Indium-111 ZEVALIN imaging dose followed by a gamma scan before administering the ZEVALIN therapeutic dose.

21 Nov 2011

ICON selected as CRO for Tasly's Dantonic pill global Phase III studies for chronic stable angina pectoris

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Tasly Pharmaceuticals for the company's global Phase III T89 trial. T89, also known as Dantonic pill, aims to become the first traditional Chinese medicine to receive FDA approval in the United States.

21 Nov 2011

Almac collaborates with Alexion for packaging and distribution of Soliris during German E. coli outbreak

Almac, a leading provider of contract services to the global pharmaceutical and biotech industries, responded earlier this year to an urgent request from their client partner, Alexion Pharmaceuticals, Inc., a global biotechnology company, for packaging and distribution of Soliris (eculizumab) for patients with STEC-HUS during the E. coli outbreak in Germany earlier this year.

21 Nov 2011

Avidocin protein could prevent or treat E. coli O157:H7-induced diarrhea

A novel antibacterial protein targeted against E. coli O157:H7 may offer a way to prevent or treat serious food-borne bacterial infections, as demonstrated in a study published in the December issue of Antimicrobial Agents and Chemotherapy.

21 Nov 2011

Switching or adding antidepressants does not exacerbate side effects

Patients with major depression who fail to see improvement after taking an antidepressant often have their initial medication switched or combined with a second drug. Many clinicians weigh the possibility of adverse side effects when deciding between strategies. New research in the latest issue of General Hospital Psychiatry now suggests one strategy may not be any more likely to be harmful than the other.

19 Nov 2011

Omega-3 linked with reduced joint pain and cognitive side effects of breast cancer therapy

"I know I need this medicine to help lower my chance of cancer recurrence, but it makes my joints ache and stiff. It makes me feel old and I am not sure I can take this medication much longer."

19 Nov 2011

New class of malaria drugs could be used as both prevention, treatment, study shows

"A group of researchers led by Novartis AG have discovered novel malaria compounds that may prove to be more efficient than currently available treatments and could be used as a prophylactic," the Wall Street Journal reports.

19 Nov 2011

Avastin drug not safe and effective for breast cancer patients: FDA Commissioner

FDA Commissioner Margaret A. Hamburg, M.D., said today she is revoking the agency's approval of the breast cancer indication for Avastin (bevacizumab) after concluding that the drug has not been shown to be safe and effective for that use.

19 Nov 2011

FDA approves EUSA's orphan drug ERWINAZE for acute lymphoblastic leukemia

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that the US Food and Drug Administration (FDA) has approved its orphan drug ERWINAZE (asparaginase Erwinia chrysanthemi) for the treatment of acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to E. coli-derived asparaginase.

19 Nov 2011

Shire, Shionogi enter agreement to co-develop and co-commercialize ADHD medicines in Japan

Shire plc, the global specialty biopharmaceutical company, announces that it has entered into an agreement with Shionogi & Co. Ltd. of Japan to co-develop and co-commercialize certain of Shire's Attention Deficit Hyperactivity Disorder (ADHD) medicines in Japan.

19 Nov 2011

Pharmaceutical News

The Chinese acute coronary syndrome drug market to grow from $326M in 2010 to $448M in 2015

ChanRx to evaluate AFIB drug, vanoxerine with closed Series A funding

SAFC commences process validation activities for Oncolytics' REOLYSIN

Australia's TGA grants market authorisation for Pierre Fabre Médicament's milnacipran to treat fibromyalgia

PLoS ONE publishes study on darinaparsin, a multivalent chemotherapeutic

Impax initiates patent challenge related to Fentora

IGI develops and submits two more ANDAs to the FDA

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Cambridge Theranostics' liquidators set deadline for offers

Mylan settles Vivelle-Dot patent litigation lawsuit with Novartis

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

ICON selected as CRO for Tasly's Dantonic pill global Phase III studies for chronic stable angina pectoris

Almac collaborates with Alexion for packaging and distribution of Soliris during German E. coli outbreak

Avidocin protein could prevent or treat E. coli O157:H7-induced diarrhea

Switching or adding antidepressants does not exacerbate side effects

Omega-3 linked with reduced joint pain and cognitive side effects of breast cancer therapy

New class of malaria drugs could be used as both prevention, treatment, study shows

Avastin drug not safe and effective for breast cancer patients: FDA Commissioner

FDA approves EUSA's orphan drug ERWINAZE for acute lymphoblastic leukemia

Shire, Shionogi enter agreement to co-develop and co-commercialize ADHD medicines in Japan

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News